$EXAS News
Last published 7mo ago
- 7mo agoEXASExact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026Business WireThe Oncodetect® test expands the role of tumor-informed MRD in triple-negative breast cancer The Cancerguard® test demonstrates improved early-stage multi-cancer detection performance Exact Sciences Corp.
- 8mo agoEXASExact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive YearBusiness WireExact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has earned the 2026 Gallup Exceptional Workplace Award (GEWA), marking the third consecutive year the
- 8mo agoEXASPRVAMarking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry CollaborationBusiness WireAmalgam Rx, Inc., Privia Health, and Exact Sciences Corp. highlight how coordinated, EHR-enabled patient outreach supported measurable screening impact at scale. Amalgam Rx, Inc., a leader in data-driven, AI-powered
- 8mo agoABTEXASExact Sciences Stockholders Approve Acquisition by AbbottBusiness WireExact Sciences Corporation (NASDAQ:EXAS) ("Exact Sciences"), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted to approve the proposed acquisition of Exact Sciences
- 9mo agoEXASExact Sciences Announces Record Fourth Quarter and Full Year 2025 ResultsBusiness WireFourth quarter and 2025 highlights Total fourth quarter revenue of $878 million, an increase of 23% on a reported and core revenue basis, with Screening revenue of $695 million and Precision Oncology revenue of $183
- 9mo agoEXASExact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway for Multi-Cancer Early Detection TestsBusiness WirePassage of MCED legislation marks major milestone for early cancer detection Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today celebrated the passage of landmark
- 9mo agoEXASOncotype DX Breast Recurrence Score® Test Surpasses 2 Million Patients WorldwideBusiness WireMilestone underscores test's significant role as a global standard-of-care in guiding personalized breast cancer treatment The predictive utility of this test helped an estimated 1.6 million patients safely avoid
- 10mo agoONCYEXASVCYTHOLX+1Smart Oncology: 5 Stocks Chasing the $317B PrizePR NewswireThe precision oncology market surged to $139.4 billion in 2025 and is racing toward $317.5 billion by 2035[1], driven by a fundamental shift in...
- 10mo agoEXASExact Sciences Shareholders Unhappy With $105 Per Share Sale to Abbott Should Contact Julie & Holleman LLP Regarding Potential ClaimsGlobeNewswireNEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Julie & Holleman LLP, a top-tier shareholder rights firm, is investigating Abbott's proposed $21 billion acquisition of Exact Sciences Corp. (NASDAQ:EXAS). Julie &
- 11mo agoEXASExact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCSBusiness WireNew data reveals Oncodetect's powerful prognostic performance in one of the largest TNBC MRD studies to date1 Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today
- 11mo agoEXASExact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer SymposiumBusiness WireFirst clinical validation of the Oncodetect ® test to be presented in triple negative breast cancer; signals highly sensitive molecular residual disease (MRD) detection The Oncotype DX® test is associated
- 11mo agoEXASEXAS Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Exact Sciences to Abbott LaboratoriesGlobeNewswireMONSEY, N.Y., Nov. 24, 2025 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Exact Sciences Corporation (NASDAQ:EXAS) ("Exact Sciences") to Abbott
- 11mo agoEXASIDYAILMNIR+6Quanterix Announces Board and Leadership Changes to Support Next Stage of GrowthBusiness WireAppoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company")
- 11mo agoABTEXASAbbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segmentsPR NewswireAbbott (NYSE: ABT) and Exact Sciences (NASDAQ: EXAS) today announced a definitive agreement for Abbott to acquire Exact Sciences, which will enable...
- 1y agoEXASExact Sciences Announces Expiration of the HSR Waiting Period for Exclusive License to Freenome's Blood-Based Colorectal Cancer Screening TestsBusiness WireExact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR)
- 1y agoEXASExact Sciences Announces Breakthrough Results from Landmark Study Demonstrating Superior Early Detection of Liver Cancer with Blood-Based Surveillance TestBusiness WireOncoguard® Liver blood test delivers seven times greater sensitivity for very early-stage hepatocellular carcinoma (HCC) versus standard of care ALTUS study is the largest prospective trial of a blood test for
- 1y agoEXASExact Sciences to Participate in November Investor ConferenceBusiness WireExact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate
- 1y agoEXASExact Sciences Announces Third Quarter 2025 ResultsBusiness WireReports record revenue, raises full-year guidance, generates record cash from operations Third quarter and recent highlights Delivered record total third quarter revenue of $851 million, an increase of 20% on a
- 1y agoEXASExact Sciences Presents New Findings at ACG 2025 Demonstrating How the Cologuard Test Helps Improve Adherence and Close Screening GapsBusiness WireStudies show higher completion rates for mt-sDNA testing and the positive impact of patient navigation in expanding access to underserved and older populations Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of
- 1y agoEXASExact Sciences Schedules Third Quarter 2025 Earnings CallBusiness WireExact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2025 financial results after the close of the U.S.
- 1y agoEXASNew Study in Journal of the National Cancer Institute Finds Cologuard Plus™ Provides the Most Life-Years Gained with the Fewest ColonoscopiesBusiness WireFirst evaluation of benefit-to-burden for new screening options using methodologies adopted by the United States Preventive Services Task Force Noninvasive test performance is critical to support patient outcomes and
- 1y agoEXASHorror Icon Matthew Lillard and Exact Sciences Help Adults 45+ Conquer Fear and Get Screened for Colon Cancer with the Cologuard® TestBusiness WireExact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, is teaming up with actor and horror icon Matthew Lillard to encourage people 45 and older to get screened for colorectal
- 1y agoEXASExact Sciences Launches Cancerguard™, First-of-Its-Kind Multi-Cancer Early Detection Blood TestBusiness WireOnly MCED test on-market to analyze multiple biomarker classes, enhancing early cancer detection Offered as a laboratory-developed test at $689 Nationwide access enabled through Quest Diagnostics' 7,000 patient
- 1y agoEXASExact Sciences Corporation (EXAS) Presents At Baird 2025 Global Healthcare Conference (Transcript)Earnings Call Transcripts
- 1y agoEXASExact Sciences Corporation (EXAS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptEarnings Call Transcripts
- 1y agoEXASExact Sciences to Participate in September Investor ConferencesBusiness WireExact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate
- 1y agoEXASExact Sciences Corporation (EXAS) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoEXASExact Sciences Announces Second Quarter 2025 ResultsBusiness WireReports record revenue, improves adjusted EBITDA, raises full-year guidance Second quarter and recent highlights Delivered record total second quarter revenue of $811 million, an increase of 16% on a reported and
- 1y agoEXASExact Sciences Announces Exclusive License with Freenome for Blood-Based Colorectal Cancer Screening TestsBusiness WireExact Sciences acquires exclusive rights to current and future versions of Freenome's blood-based colorectal cancer screening tests Freenome submitted the final module of the premarket approval application to the FDA
- 1y agoEXASExact Sciences and Humana Expand Colorectal Cancer Screening Partnership with Cologuard Plus™ TestBusiness WireCologuard Plus™ Available In-Network August 2025 Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced an expanded partnership with Humana Inc. to
- 1y agoEXASExact Sciences Schedules Second Quarter 2025 Earnings CallBusiness WireExact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2025 financial results after the close of the U.S.
- 1y agoEXASExact Sciences Announces Medicare Coverage for Oncodetect™ Molecular Residual Disease Test in Colorectal CancerBusiness WireExact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) test has received Medicare coverage through
- 1y agoEXASExact Sciences Corporation vs Geneoscopy, Inc. - AIA Trial, Final Written DecisionUS Patent Trial and Appeal Board
- 1y agoEXASExact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation RoadmapBusiness WireBeta-CORRECT study to be presented at ASCO 2025 confirms the clinical utility of the molecular residual disease (MRD) test, Oncodetect™, for recurrence monitoring in stage II–IV colorectal cancer Whole-genome
- 1y agoEXASExact Sciences to Participate in June Investor ConferenceBusiness WireExact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate
- 1y agoEXASExact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025Business WireExact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present ten abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting,
- 1y agoEXASExact Sciences Earns 2025 Great Place To Work® Certification™Business WireAward marks seventh consecutive year company has received prestigious distinction Exact Sciences (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, announced today that it has been certified as
- 1y agoEXASExact Sciences to Participate in May Investor ConferenceBusiness WireExact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate
- 1y agoEXASExact Sciences Announces First-Quarter 2025 ResultsBusiness WireFirst quarter highlights Delivered total first quarter revenue of $707 million, an increase of 11% on a reported and core revenue basis, including Screening revenue of $540 million and Precision Oncology revenue of
- 1y agoEXASExact Sciences to Highlight Cologuard® Test Adherence and Predicted Preference Data at Digestive Disease Week (DDW) 2025Business WireRobust research and data from multiple abstracts predict the Cologuard® test as the top choice for screening average-risk adults 45 and older, and confirms adoption across diverse demographics Exact Sciences Corp.
- 1y agoEXASExact Sciences Launches the Oncodetect™ Molecular Residual Disease TestBusiness WireThe new, highly sensitive, tumor-informed test detects up to 200 ctDNA* variants, identifying signs of colorectal cancer (CRC) recurrence up to two years earlier than imaging—making it one of the most comprehensive
- 1y agoEXASJAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic GroupsBusiness WireComprehensive review confirms that the Oncotype DX Breast Recurrence Score® test accurately predicts breast cancer outcomes and chemotherapy benefit for patients regardless of race or ethnicity Exact Sciences
- 1y agoEXASExact Sciences Schedules First Quarter 2025 Earnings CallBusiness WireExact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2025 financial results after the close of the U.S.
- 1y agoEXASExact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer ScreeningBusiness WireThe Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most accurate noninvasive CRC screening test reported in studies to date Exact Sciences Corp.
- 1y agoSERAQTRXEXASSERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWNPR NewswireSera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy...
- 1y agoEXASExact Sciences Named 2025 Gallup Exceptional Workplace Award WinnerBusiness WireExact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has received the 2025 Gallup Exceptional Workplace Award (GEWA), marking the second year in a row the
- 1y agoEXASExact Sciences to Participate in March Investor ConferencesBusiness WireExact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate
- 1y agoEXASExact Sciences Announces Fourth Quarter 2024 ResultsBusiness WireFourth quarter and 2024 highlights Total fourth quarter revenue of $713 million, an increase of 10%, or 11% on a core revenue basis, with Screening revenue of $553 million and Precision Oncology revenue of $161
- 1y agoEXASExact Sciences Corporation vs Geneoscopy, Inc. - AIA Trial, Institution GrantedUS Patent Trial and Appeal Board
- 1y agoEXASGEGMEDXRAYDentsply Sirona Appoints Michael Barber and Daniel Scavilla as New Board MembersGlobeNewswireCHARLOTTE, N.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Michael J. Barber and Daniel T. Scavilla have been appointed to